LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Canertinib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1687 | 4223 | 0.3996 | 0.1014 |
| SK-BR-3 | Celastrol | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3535 | 4223 | 0.8371 | 0.7561 |
| SK-BR-3 | CGP60474 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3015 | 4223 | 0.7139 | 0.5718 |
| SK-BR-3 | CGP60474 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1013 | 4223 | 0.2400 | -0.1375 |
| SK-BR-3 | CHIR-99021 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3900 | 4223 | 0.9236 | 0.8856 |
| SK-BR-3 | CP724714 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 2814 | 4223 | 0.6665 | 0.5008 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4299 | 4223 | 1.0181 | 1.0270 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3970 | 4223 | 0.9401 | 0.9103 |
| SK-BR-3 | Momelotinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4144 | 4223 | 0.9814 | 0.9721 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4468 | 4223 | 1.0582 | 1.0870 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3851 | 4223 | 0.9121 | 0.8684 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3385 | 4223 | 0.8016 | 0.7030 |
| SK-BR-3 | Enzastaurin | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4234 | 4223 | 1.0027 | 1.0041 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3908 | 4223 | 0.9254 | 0.8883 |
| SK-BR-3 | Foretinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4409 | 4223 | 1.0440 | 1.0659 |
| SK-BR-3 | R406 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 4060 | 4223 | 0.9615 | 0.9424 |
| SK-BR-3 | Pictilisib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 2262 | 4223 | 0.5357 | 0.3051 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3569 | 4223 | 0.8452 | 0.7683 |
| SK-BR-3 | Geldanamycin | 0.12 | uM | LJP5 | 72 | hr | 1401 | 1560 | 4223 | 0.3695 | 0.0563 |
| SK-BR-3 | Geldanamycin | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1486 | 4223 | 0.3520 | 0.0302 |
| SK-BR-3 | GSK1059615 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3743 | 4223 | 0.8865 | 0.8301 |
| SK-BR-3 | GSK1059615 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3420 | 4223 | 0.8099 | 0.7155 |
| SK-BR-3 | GSK1904529A | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3770 | 4223 | 0.8927 | 0.8394 |
| SK-BR-3 | Omipalisib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1362 | 4223 | 0.3226 | -0.0139 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 2932 | 4223 | 0.6944 | 0.5427 |